About this trial
The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and/or biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the development of lung disease.
Eligibility criteria
Qualifiers
≥ 45years old
Diagnosis of RA using the 2010 American College of Rheumatology (ACR) criteria
Disqualifiers
Inability to give informed consent
Pregnant women
History of interstitial lung disease
Evidence of other causes of diffuse parenchymal lung disease such as infection, drug toxicity, other autoimmune processes, etc.
Trial design
Treatments tested in this trial
- Not listed